一种针对流感和COVID-19的非性复合mRNA疫苗
Yang Wang1,2, Qinhai Ma1, Man Li3
1State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
mBio
|August 6, 2024
概括
一种新的10价值mRNA疫苗FLUCOV-10显示出对季节性和禽流感以及多种SARS-CoV-2变异的承诺. 临床前研究在小鼠中证明了完全的保护,突出了其预防呼吸系统疾病的潜力.
科学领域:
- 疫苗学 疫苗学 疫苗学
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 随着COVID-19大流行和流感的复苏,全球卫生面临着重大挑战.
- SARS-CoV-2 和流感病毒的同时传播增加了社区负担.
- 像禽类A/H5N1和A/H7N9这样的动物性流感病毒仍然是一个大流行问题.
研究的目的:
- 开发一种新型的多价值mRNA疫苗 (FLUCOV-10) 针对流感和SARS-CoV-2.
- 在临床前模型中评估FLUCOV-10的免疫性和保护效果.
主要方法:
- 开发一种编码来自六种流感菌株 (四种季节性,两种禽类) 的血凝素 (HA) 和来自四种SARS-CoV-2变种的尖端蛋白的10价值mRNA疫苗.
- 用FLUCOV-10对小鼠进行两剂免疫接种.
- 评估IgG抗体,中和抗体和细胞免疫反应.
- 挑战对同源和异源流感和SARS-CoV-2菌株的研究.
主要成果:
- FLUCOV-10免疫引发了强大的IgG,中和抗体,以及针对所有疫苗成分的抗原特异性细胞免疫反应.
- 在小鼠模型中观察到对同源和异源的流感菌株和SARS-CoV-2的完整保护.
- 该疫苗证明了对各种病毒菌株的广泛保护.
结论:
- FLUCOV-10是预防流感和COVID-19的有希望的疫苗候选人.
- mRNA疫苗技术为解决当前和未来的呼吸道病毒威胁提供了灵活和有效的平台.
- 这种多价值的方法可以简化疫苗接种策略,提高全球卫生安全.
相关概念视频
02:28Leaky Scanning
5.1K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.1K
01:51Vaccinations
44.2K
Overview
44.2K
00:57Viral Recombination
23.3K
Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
23.3K
01:29Immune Response Against Viral Pathogens
766
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
766
01:30Cancer Vaccines
347
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
347